Clementi M, Bagnarelli P, Manzin A, Menzo S
Institute of Microbiology, University of Ancona, Italy.
Genet Anal Tech Appl. 1994;11(1):1-6. doi: 10.1016/1050-3862(94)90002-7.
Due to the high sensitivity level (which can be pushed to the limit of one molecule) and its extraordinary flexibility, the polymerase chain reaction (PCR) is the method of choice for the detection of nucleic acids present in very low concentration in biological samples. Since the qualitative features of PCR amplification have limited its use, several PCR-based approaches for the quantitation of low-abundance nucleic acid species have been planned and proposed in the last few years. Recently, different lines of evidence have indicated that competitive PCR and competitive reverse-transcription-PCR share several advantages over other quantitative approaches. This evidence opens up unexpected possibilities in many biological fields, including virology; in fact, availability of reliable techniques for the absolute quantitation of DNA and RNA species may be the key to a better understanding of the pathogenic steps of most viral diseases and for a more precise monitoring of patients treated with specific antiviral compounds. In this review article, we summarize the procedures adopted for this quantitative molecular approach; additionally, several important technical aspects to plan novel competitive PCR-based applications are analyzed, and early results obtained using cPCR for the direct evaluation of viral activity in vivo are discussed.
由于其高灵敏度(可达到单分子水平)及其非凡的灵活性,聚合酶链反应(PCR)是检测生物样品中极低浓度核酸的首选方法。由于PCR扩增的定性特性限制了其应用,在过去几年中,已经设计并提出了几种基于PCR的低丰度核酸物种定量方法。最近,不同的证据表明,竞争性PCR和竞争性逆转录PCR比其他定量方法具有多个优势。这些证据在包括病毒学在内的许多生物学领域开辟了意想不到的可能性;事实上,可靠的DNA和RNA物种绝对定量技术的可用性可能是更好地理解大多数病毒性疾病致病步骤以及更精确监测接受特定抗病毒化合物治疗患者的关键。在这篇综述文章中,我们总结了这种定量分子方法所采用的程序;此外,分析了规划基于竞争性PCR的新应用的几个重要技术方面,并讨论了使用cPCR直接评估体内病毒活性的早期结果。